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Conclusion. Clinical and toxicity outcomes of LALC patients integrating the use of 18 FDG PET-CT, IMRT and IGRT at our institution
are comparable than pivotal studies of organ preservation (RTOG 91-11).
http://dx.doi.org/10.1016/j.rpor.2013.03.272
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Introduction. Lymphoepithelial carcinoma (LC) is an undifferentiated carcinoma epithelial cell non-keratinized. Nasopharynx and
oropharynx are the most common involved sites, and salivary glands as primary origin of a LC are unusually seen. We report the
case of a patient diagnosed of a LC of the parotid gland.
Material and methods. Male 28 years old with no medical history who noticed a right retromandibular tumor, which had grown
slowly and persistently over an unspeciﬁed period of time without other symptoms. After ENT evaluation a superﬁcial parotidec-
tomy was performed. Pathological diagnosis conﬁrmed a 25mm LC contacting surgical plane. A PET-CT ruled out nasopharyngeal
disease but conﬁrmed cervical nodal involvement. A right neck dissection was done demonstrating multiple nodal metastases
(3/14) on pathological report, TNM stage pT2N2bM0. Treatment given: Docetaxel/Cisplatin/5FU one cycle. Then concomitant
radiochemotherapy weekly Carboplatin plus 3D-EBRT 50Gy to risk sites of subclincal involvement The right side of the neck and
parotid bed received up to 66Gy.
Results. The patient completed treatment according to the standard protocol of nasopharynx LC. After ﬁrst cycle of chemotherapy
he was hospitalized for febrile neutropenia. Moreover, he presented Grade IV hematologic toxicity, mucosal and cutaneous
toxicity grade 2, related to EBRT. After two years of follow up the patient is free of disease.
Conclusion. After reviewing the most recent literature, we can conclude that LC in non-nasopharyngeal is a rare condition. Given
the rarity of this tumor, the optimal treatment is not deﬁned. Parotid surgery is performed as part of the usual treatment of
a parotid tumor and concomitant radiochemotherapy treatment is carried out following the usual protocol of nasopharyngeal
carcinomas. The prognosis of these patients seems better than primary nasopharyngeal LC.
http://dx.doi.org/10.1016/j.rpor.2013.03.273
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Background and purpose. The anatomy, etiologic factors, natural history and treatment of malignant tumors of the nasopharynx
make this disease a distinct group among head and neck cancer. This study aims to evaluate the initial response and disease-
free survivors of nasopharynx cancer treated according to the stage with radiotherapy alone or radiotherapy and concurrent
chemotherapy followed by adjuvant chemotherapy.
Material and methods. From April 2001 to December 2012, 51 patients, 40 men and 11 women, mean age 61.5 years (range from
35 to 88) with nasopharyngeal cancer were treated in our department. We include 7 patients (13.72%) with stage I, 8 patients
(15.68%) with stage II and 36 patients (70.6%) with advanced stage disease (stage III and IV). Stage I patients received 3D conformal
radiotherapy alone with standard fractioning and total dose of 70Gy. Five patients with stage IV (9.8%) were also treated with
RT alone because of their poor performance status. Radiochemotherapy followed by adjuvant chemotherapy was the treatment
of choice in the other 39 patients (76.47%) with stages II–IV. 12 patients (27.3%) did not complete treatment due to side effects.
Intensity Modulated Radiation Therapy is available in our hospital from May 2011. This technique was applied to the last 7
patients of our series.
Results. 37 patients (72.54%) showed a complete radiological and clinical response after completing treatment. Currently, disease-
free survivors are 66.66% (34 patients). 15.68% (8 patients), all of them with stage IV disease, died because of disease progression
during this period, with a median survival of 11 months (range 4–16 months). 11.76% (6 patients) died of secondary neoplasia
or other underlying diseases and 1 patient died of chemotherapy toxicity during the treatment. Xerostomia and mucositis were
the most common detected acute toxicities.
Conclusions. Our results with radiotherapy and concurrent chemotherapy followed by adjuvant chemotherapy in patients with
nasopharynx cancer match published data. There are few patients treated with Intensity Modulated Radiation Therapy, so we
cannot still compare results in response and toxicity with conventional techniques.
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